From the link20 Nov 2023 14:52
Applications
Optimer technology has been developed and commercialised by Aptamer Group, who are developing these affinity reagents as biotherapeutics and diagnostic tools.
Therapeutics
Optimer ligands are being investigated for use in drug discovery and development. The small size and stability profile of Optimer ligands combined with the lack of immunogenicity confer good drug-like properties on these molecules. In a similar manner to antibody therapeutics, Optimer therapeutics can be used as direct agonists or antagonists for the development of novel therapeutic moieties.[16] Additionally, Optimers can be used as conjugates for the targeted delivery of a range of drug cargo, such as chemotherapeutics,[14] gene silencing therapeutics,[22] and radionuclides.
Optimer therapeutics are being developed in partnership with Cancer Research UK that can selectively target a key gene fault for the treatment of Chronic Myelomonocytic Leukaemia (CMML) and other myeloid malignancies.[16]
Optimer conjugate therapies are being developed in partnership with AstraZeneca[22] and PinotBio.[14]